BioNTech, OncoC4 Phase 3 study put on partial hold by FDA
BioNTech (NASDAQ:BNTX) and OncoC4 have had a partial clinical hold placed by the FDA on a Phase 3 study for their drug ...
FierceBiotech6h
BioNTech-OncoC4 phase 3 cancer trial under partial hold after varying results reported
The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing ...
BioNTech shares slip as FDA places partial clinical hold on lung cancer study
BioNTech (NASDAQ:BNTX) shares fell Friday after the company said it had been informed by partner OncoC4 that FDA placed ...
The Pharma Letter23h
FDA puts partial clinical hold on gotistobart trial
BioNTech (Nasdaq: BNTX) and partner USA-based OncoC4 understand that the partial clinical hold in the ongoing Phase III trial ...
FierceBiotech23d
OncoC4 founders take own science under their wing in new biotech merger
OncoC4 is taking AcroImmune—and its in-house clinical manufacturing capabilities—under its wing in an all-stock merger. Both cancer biotechs were co-founded by OncoC4 CEO Yang Liu, Ph.D., and ...
Yahoo Finance23d
OncoC4 and AcroImmune Announce Merger
ROCKVILLE, Md., Sept. 25, 2024 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer, and AcroImmune, a ...
Yahoo Finance1mon
OncoC4 Announces First Patient Dosed in Phase 1 Trial for Novel SIGLEC10 Immune Checkpoint Inhibitor ONC-841 for Solid Tumors
ROCKVILLE, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- OncoC4, Inc. (“OncoC4”), a late-stage biopharmaceutical company developing novel medicines for cancer and immunological diseases, today ...
PipelineReview.com23d
OncoC4 and AcroImmune Announce Merger
Under the terms of the agreements, OncoC4 will acquire 100% of the outstanding equity interests of AcroImmune. Upon completion of the Merger, the combined company is expected to operate under the name ...
Mena FN23d
Oncoc4 And Acroimmune Announce Merger
Sept. 25, 2024 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer, and AcroImmune, a biopharmaceutical company developing immunotherapy ...